製品番号: HY-B1752

Quinpirole

(別名: LY 171555; (-)-LY 141865)

4 Cited Publications

カスタマーレビュー

Based on 4 publication(s) in Google Scholar

Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor agonist and a CaV1.3 calcium channel modulator. Quinpirole normalizes dendritic spine density in dopamine-depleted striatum, upregulates the protein expression of BCL2 and GluR2, downregulates the protein expression of BAX, and delays the onset of seizures. Quinpirole enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and induces anxiety-like, stereotyped, and compulsive behaviors. Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances the activity of paraventricular thalamic neurons to promote recovery from Isoflurane anesthesia, and alters the composition of the gut microbiota in rats. Quinpirole can be used in research related to dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorder, obsessive-compulsive disorder, and schizophrenia.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.95%
CAS 番号: 80373-22-4
分子式: C₁₃H₂₁N₃
分子量:219.33

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Quinpirole 構造式

CAS 番号: 80373-22-4

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (4)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

Dopamine Receptor アイソフォーム固有の製品をすべて表示 :

Calcium Channel アイソフォーム固有の製品をすべて表示 :

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

iGluR アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	1.4 nM Compound: Quinpirole	Effective concentration in [3H]thymidine uptake assay by CHO dhfr- mutant cells expressing human D3 receptor Effective concentration in [3H]thymidine uptake assay by CHO dhfr- mutant cells expressing human D3 receptor	[PMID: 15916420]
CHO	EC₅₀	1.4 nM Compound: quinpirole	Activity at human D4.2 receptor assessed as [3H]thymidine incorporation in CHO 10001 cells by mitogenesis assay Activity at human D4.2 receptor assessed as [3H]thymidine incorporation in CHO 10001 cells by mitogenesis assay	[PMID: 16789750]
CHO	EC₅₀	1.4 nM Compound: Quinpirole	Agonist activity at human dopamine D3 receptor expressed in dhfr-deficient CHO cells assessed as [3H]thymidine incorporation Agonist activity at human dopamine D3 receptor expressed in dhfr-deficient CHO cells assessed as [3H]thymidine incorporation	[PMID: 21273071]
CHO	EC₅₀	10 nM Compound: quinpirole	Intrinsic activity against dopamine D2(short) receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay Intrinsic activity against dopamine D2(short) receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay	[PMID: 16563764]
CHO	EC₅₀	10 nM Compound: quinpirole	Agonist activity at human dopamine D4.2 receptor expressed in CHO dhfr mutant cells assessed as stimulation of mitogenesis after 2 hrs Agonist activity at human dopamine D4.2 receptor expressed in CHO dhfr mutant cells assessed as stimulation of mitogenesis after 2 hrs	[PMID: 17827018]
CHO	EC₅₀	11 nM Compound: quinpirole	Intrinsic activity against dopamine D4 receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay Intrinsic activity against dopamine D4 receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay	[PMID: 16563764]
CHO	EC₅₀	140 nM Compound: Quinpirole	Agonist activity at DRD2 Long receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation by bioluminescence assay Agonist activity at DRD2 Long receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation by bioluminescence assay	[PMID: 21999579]
CHO	EC₅₀	2 nM Compound: Quinpirole	Tested for the effective concentration against CHO 10001 cells in human D4.2 receptor established in mitogenesis assay Tested for the effective concentration against CHO 10001 cells in human D4.2 receptor established in mitogenesis assay	[PMID: 11844688]
CHO	EC₅₀	2.1 nM Compound: quinpirole	Intrinsic activity at human D3 receptor expressed in CHO dhfr- cells by [3H]thymidine incorporation assay Intrinsic activity at human D3 receptor expressed in CHO dhfr- cells by [3H]thymidine incorporation assay	[PMID: 18834111]
CHO	EC₅₀	2.6 nM Compound: quinpirole	Intrinsic activity at human D3 receptor expressed in CHO dhfr- cells assessed as rate of [3H]thymidine incorporation by mitogenesis assay Intrinsic activity at human D3 receptor expressed in CHO dhfr- cells assessed as rate of [3H]thymidine incorporation by mitogenesis assay	[PMID: 16759104]
CHO	EC₅₀	2.9 nM Compound: quinpirole	Intrinsic activity at human D3 receptor expressed in CHO dhfr- cells assessed as inhibition of forskolin-induced cAMP release Intrinsic activity at human D3 receptor expressed in CHO dhfr- cells assessed as inhibition of forskolin-induced cAMP release	[PMID: 18834111]
CHO	EC₅₀	23 nM Compound: quinpirole	Intrinsic activity against dopamine D4 receptor expressed in CHO cells by GTPgammaS assay Intrinsic activity against dopamine D4 receptor expressed in CHO cells by GTPgammaS assay	[PMID: 16563764]
CHO	EC₅₀	230 nM Compound: quinpirole	Intrinsic activity against dopamine D2(short) receptor expressed in CHO cells by GTPgammaS assay Intrinsic activity against dopamine D2(short) receptor expressed in CHO cells by GTPgammaS assay	[PMID: 16563764]
CHO	EC₅₀	3.1 nM Compound: Quinpirole	Intrinsic activity in mitogenesis assay using Dopamine receptor D3 expressing CHO cells Intrinsic activity in mitogenesis assay using Dopamine receptor D3 expressing CHO cells	[PMID: 12361386]
CHO	EC₅₀	3.4 nM Compound: quinpirole	Intrinsic activity against dopamine D3 receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay Intrinsic activity against dopamine D3 receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay	[PMID: 16563764]
CHO	EC₅₀	330 nM Compound: quinpirole	Intrinsic activity against dopamine D2(long) receptor expressed in CHO cells by GTPgammaS assay Intrinsic activity against dopamine D2(long) receptor expressed in CHO cells by GTPgammaS assay	[PMID: 16563764]
CHO	EC₅₀	5.2 nM Compound: quinpirole	Agonist activity at human dopamine D3 receptor expressed in CHO dhfr mutant cells assessed as stimulation of mitogenesis after 4 hrs Agonist activity at human dopamine D3 receptor expressed in CHO dhfr mutant cells assessed as stimulation of mitogenesis after 4 hrs	[PMID: 17827018]
CHO	EC₅₀	7.4 nM Compound: quinpirole	Intrinsic activity against dopamine D2(long) receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay Intrinsic activity against dopamine D2(long) receptor assessed as [3H]thymidine uptake in CHO cells by mitogenesis assay	[PMID: 16563764]
CHO	EC₅₀	9.9 nM Compound: Quinpirole	Effective concentration for [3H]thymidine uptake in growing CHO cells stably expressing the dopamine D4.2 receptor Effective concentration for [3H]thymidine uptake in growing CHO cells stably expressing the dopamine D4.2 receptor	[PMID: 12617906]
CHO-K1	EC₅₀	49 nM Compound: Quinpirole	Effective concentration for [35S]GTP-gamma-S, binding in CHO-K1 cells expressing human dopamine D4 receptor Effective concentration for [35S]GTP-gamma-S, binding in CHO-K1 cells expressing human dopamine D4 receptor	[PMID: 15916420]
CHO-K1	EC₅₀	49 nM Compound: quinpirole	Activity at human D4.4 receptor expressed in CHOK1 cells assessed as stimulation of [35S]GTP-gammaS binding Activity at human D4.4 receptor expressed in CHOK1 cells assessed as stimulation of [35S]GTP-gammaS binding	[PMID: 16789750]
COS-7	IC₅₀	1362 nM Compound: Quinpirole	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	25 nM Compound: Quinpirole	Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D3 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D3 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	29 nM Compound: Quinpirole	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D3 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	4321 nM Compound: Quinpirole	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D2 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	454 nM Compound: Quinpirole	Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) chimeric dopamine D2 trunk/D3 tail receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
COS-7	IC₅₀	4784 nM Compound: Quinpirole	Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D2 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting Displacement of [3H]nemonapride from Rattus norvegicus (rat) wild type dopamine D2 receptor transfected in african green monkey COS7 cells after 1 hr by beta scintillation counting	10.1007/s00044-004-0006-x
GH4-C1	EC₅₀	7.6 nM Compound: quinpirole	In vitro inhibition of forskolin-stimulated cAMP accumulation in GH4C1 cells transfected with the human Dopamine D2 receptor In vitro inhibition of forskolin-stimulated cAMP accumulation in GH4C1 cells transfected with the human Dopamine D2 receptor	[PMID: 7990124]
HEK293	EC₅₀	1.3 nM Compound: Quinpirole	Agonist activity at D2R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gi-cAMP Glosensor assay Agonist activity at D2R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gi-cAMP Glosensor assay	[PMID: 31098001]
HEK293	EC₅₀	1.6 nM Compound: Quinpirole	Agonist activity at human D2S receptor expressed in HEK293 cells cotransfected with Gqi5 protein assessed as [3H]IP3 accumulation after 120 mins by scintillation counting assay in presence of myo-[3H]-inositol Agonist activity at human D2S receptor expressed in HEK293 cells cotransfected with Gqi5 protein assessed as [3H]IP3 accumulation after 120 mins by scintillation counting assay in presence of myo-[3H]-inositol	[PMID: 27132867]
HEK293	EC₅₀	10 nM Compound: quinpirole	Activation of human dopamine D3 receptor L89K mutant expressed in HEK293 cells co-expressing GaqG66Di5- incubated for 120 mins by scintillation counting based myo-[3H]inositol phosphate accumulation assay Activation of human dopamine D3 receptor L89K mutant expressed in HEK293 cells co-expressing GaqG66Di5- incubated for 120 mins by scintillation counting based myo-[3H]inositol phosphate accumulation assay	[PMID: 25564378]
HEK293	EC₅₀	10.9 nM Compound: (-)-Quinpirole	Agonist activity at human dopamine D2 receptor expressed in HEK293 cells assessed as cAMP inhibition by BRET assay Agonist activity at human dopamine D2 receptor expressed in HEK293 cells assessed as cAMP inhibition by BRET assay	[PMID: 28300398]
HEK293	EC₅₀	147.6 nM Compound: (-)-Quinpirole	Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay	[PMID: 28300398]
HEK293	EC₅₀	1600 nM Compound: Quinpirole	Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphai2 after 30 mins by [35S]GTPgammaS binding assay Agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells co-expressing Galphai2 after 30 mins by [35S]GTPgammaS binding assay	[PMID: 24831693]
HEK293	EC₅₀	1600 nM Compound: quinpirole	Intrinsic activity at human dopamine D2S receptor expressed in HEK293 cells co-transfected with Galpha0i assessed as [35S]GTPgammaS binding after 30 mins by [35S]GTPgammaS incorporation assay Intrinsic activity at human dopamine D2S receptor expressed in HEK293 cells co-transfected with Galpha0i assessed as [35S]GTPgammaS binding after 30 mins by [35S]GTPgammaS incorporation assay	[PMID: 25734236]
HEK293	EC₅₀	2.4 nM Compound: quinpirole	Activation of wild type human dopamine D3 receptor expressed in HEK293 cells co-expressing GaqG66Di5- incubated for 120 mins by scintillation counting based myo-[3H]inositol phosphate accumulation assay Activation of wild type human dopamine D3 receptor expressed in HEK293 cells co-expressing GaqG66Di5- incubated for 120 mins by scintillation counting based myo-[3H]inositol phosphate accumulation assay	[PMID: 25564378]
HEK293	EC₅₀	2.7 nM Compound: Quinpirole	Agonist activity at D4R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gi-cAMP Glosensor assay Agonist activity at D4R (unknown origin) expressed in HEK293 cells assessed as effect on cAMP accumulation incubated for 10 mins by Gi-cAMP Glosensor assay	[PMID: 31098001]
HEK293	EC₅₀	2300 nM Compound: quinpirole	Intrinsic activity at human dopamine D2S receptor expressed in HEK293 cells co-transfected with Galphai2 assessed as [35S]GTPgammaS binding after 30 mins by [35S]GTPgammaS incorporation assay Intrinsic activity at human dopamine D2S receptor expressed in HEK293 cells co-transfected with Galphai2 assessed as [35S]GTPgammaS binding after 30 mins by [35S]GTPgammaS incorporation assay	[PMID: 25734236]
HEK293	EC₅₀	240 nM Compound: Quinpirole	Agonist activity at dopamine D2 receptor expressed in HEK293 cells by by [35S]GTPgammaS binding assay Agonist activity at dopamine D2 receptor expressed in HEK293 cells by by [35S]GTPgammaS binding assay	[PMID: 19559623]
HEK293	EC₅₀	2700 nM Compound: quinpirole	Intrinsic activity at human dopamine D2L receptor expressed in HEK293 cells co-transfected with Galpha0i assessed as [35S]GTPgammaS binding after 30 mins by [35S]GTPgammaS incorporation assay Intrinsic activity at human dopamine D2L receptor expressed in HEK293 cells co-transfected with Galpha0i assessed as [35S]GTPgammaS binding after 30 mins by [35S]GTPgammaS incorporation assay	[PMID: 25734236]
HEK293	EC₅₀	2800 nM Compound: quinpirole	Intrinsic activity at human dopamine D2L receptor expressed in HEK293 cells co-transfected with Galphai2 assessed as [35S]GTPgammaS binding after 30 mins by [35S]GTPgammaS incorporation assay Intrinsic activity at human dopamine D2L receptor expressed in HEK293 cells co-transfected with Galphai2 assessed as [35S]GTPgammaS binding after 30 mins by [35S]GTPgammaS incorporation assay	[PMID: 25734236]
HEK293	EC₅₀	353.2 nM Compound: (-)-Quinpirole	Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay	[PMID: 28300398]
HEK293	EC₅₀	360 nM Compound: Quinpirole	Agonist activity at human D2SR expressed in HEK293 cell membranes co-expressing PTX insensitive variant of Galphao1 incubated for 30 mins by [35S]GTP-gammaS binding assay Agonist activity at human D2SR expressed in HEK293 cell membranes co-expressing PTX insensitive variant of Galphao1 incubated for 30 mins by [35S]GTP-gammaS binding assay	[PMID: 28870802]
HEK293	EC₅₀	38.7 nM Compound: (-)-Quinpirole	Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay	[PMID: 28300398]
HEK293	EC₅₀	5 nM Compound: quinpirole	Activity at human dopamine D4.4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production Activity at human dopamine D4.4 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production	[PMID: 17154515]
HEK293	EC₅₀	51 nM Compound: quinpirole	Activity at pro-link-tagged D2S-ARMS2PK2 (unknown origin) expressed in HEK293 cells by beta-arrestin-2 recruitment assay Activity at pro-link-tagged D2S-ARMS2PK2 (unknown origin) expressed in HEK293 cells by beta-arrestin-2 recruitment assay	[PMID: 26299826]
HEK293	EC₅₀	73 nM Compound: Quinpirole	Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay	[PMID: 28870802]
HEK293	EC₅₀	83 nM Compound: quinpirole	Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay	[PMID: 25734236]
HEK293	EC₅₀	83 nM Compound: Quinpirole	Agonist activity at PKA-tagged D4 receptor (unknown origin) expressed in HEK293 cells co-expressing beta-arrestin2 assessed as induction of beta-arrestin2 recruitment incubated for 6 hrs by Path-Hunter assay Agonist activity at PKA-tagged D4 receptor (unknown origin) expressed in HEK293 cells co-expressing beta-arrestin2 assessed as induction of beta-arrestin2 recruitment incubated for 6 hrs by Path-Hunter assay	[PMID: 31613617]
HEK293	EC₅₀	86 nM Compound: Quinpirole	Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay	[PMID: 27132867]
HEK293	EC₅₀	9 nM Compound: quinpirole	Activity at rat dopamine D2L receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production Activity at rat dopamine D2L receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP production	[PMID: 17154515]
HEK293	EC₅₀	9.7 nM Compound: Quinpirole	Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay Agonist activity at human dopamine D3 receptor transiently expressed in HEK293 cells co-expressing Galphao1 after 30 mins by [35S]GTPgammaS binding assay	[PMID: 24831693]
HEK-293T	EC₅₀	16 nM Compound: Quinpirole	Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay	[PMID: 28489379]
HEK-293T	EC₅₀	270 nM Compound: Quinpirole	Agonist activity at human D2S receptor expressed in HEK293T cell membranes coexpressing Galphao1 assessed as induction of nucleotide exchange preincubated for 30 mins followed by addition of [35S]GTPgammaS measured after 30 mins by [35S]GTPgammaS binding Agonist activity at human D2S receptor expressed in HEK293T cell membranes coexpressing Galphao1 assessed as induction of nucleotide exchange preincubated for 30 mins followed by addition of [35S]GTPgammaS measured after 30 mins by [35S]GTPgammaS binding	[PMID: 28489379]
HEK-293T	EC₅₀	52 nM Compound: Quinpirole	Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay	[PMID: 28489379]

体外実験

Quinpirole selectively inhibits high-voltage activated calcium channels in dopamine-depleted rat striatal medium spiny neurons, an effect dependent on L-type calcium channel activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Quinpirole (0.05-0.1 mg/kg; subcutaneous injection; twice daily for 4 weeks) consistently and significantly inhibits Levodopa (HY-N0304)-induced dyskinesia and prevents the formation of aberrant mushroom-shaped dendritic spines in the dopamine-depleted striatum of Parkinson's disease rats^[1].
Quinpirole (0.1-3 mg/kg; subcutaneous injection) exerts significant analgesic effects in mechanical nociception tests conducted on untreated male Wistar rats, complete Freund's adjuvant (CFA)-induced inflammatory pain models, and chronic constriction injury (CCI)-induced neuropathic pain models, and also produces significant nociceptive enhancement effects^[2].
Quinpirole (intracerebroventricular injection; single dose; 60 minutes prior to Pilocarpine injection) exerts neuroprotective effects on Wistar rats with epilepsy induced by Lithium chloride (HY-Y0649D)-Pilocarpine (HY-B0726A), delays the onset of seizures, improves cognitive function, and regulates the protein expression of GluR2, BAX and BCL2 in hippocampal tissue^[3].
Quinpirole (0.01-3 mg/kg, i.p., 1-4 h prior to sacrifice) dose-dependently decreases the concentrations of epinephrine in the hypothalamus and dopamine metabolites in the cerebral hemispheres of rats; at high doses, it also alters the concentrations of dopamine and norepinephrine in the hypothalamus as well as MHPG sulfate in the brain stem^[4].
Quinpirole (5.5-50 μM; immersion; single 24-hour exposure; at 5 dpf) induces persistent anxiety-like behaviors, stereotypic swimming, and aversive memory impairment in adult zebrafish, with no effect on their social or aggressive behaviors^[5].
Quinpirole (7-70 nM; bilateral intracranial infusion into the nucleus accumbens core; 0.2 μl/min) impairs prepulse inhibition of the acoustic startle reflex^[6].
Quinpirole (0.5 mg/kg, subcutaneous injection, twice weekly for 5 weeks) induces obsessive-compulsive-like behaviors, neuroinflammatory changes, intestinal histological alterations, reduced fecal short-chain fatty acid levels, and intestinal dysbiosis in adult male Wistar rats^[7].
Quinpirole (4 mM via microinjection into the paraventricular nucleus of the thalamus, with a total volume of 0.5 μl and a delivery duration of 2 minutes) significantly shortens the recovery time from Isoflurane (HY-A0134) anesthesia, reduces the cortical burst suppression ratio, and enhances the neuronal activity of the paraventricular nucleus of the thalamus in male C57BL/6J mice^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (adult male, 250g, unilateral stereotaxic injection of 6-hydroxydopamine hydrobromide to induce Parkinson's disease)^[1]
Dosage:

0.1 mg/kg (first 12 days); 0.05 mg/kg (remainder of experiment)
Administration:

s.c.; twice daily; 4 weeks
Result:

Suppressed total levodopa-induced dyskinesia (LID) severity significantly compared to vehicle controls on day 5 and day 10 of levodopa treatment.
Reduced peak LID severity significantly compared to vehicle controls on day 10.
Dampened LID severity significantly compared to vehicle controls at the 70-minute post-levodopa peak of LID expression on day 10.
Showed no significant difference in total spine density and thin spine density between dopamine-depleted and intact striatum, unlike vehicle-treated rats.
Prevented the significant increase in mushroom spine density in the dopamine-depleted striatum observed in vehicle-treated dyskinetic rats.

Animal Model:

Wistar (male, 220-350 g)^[2]
Dosage:

0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg
Administration:

s.c.
Result:

Showed no significant changes in thermonociceptive withdrawal latencies or AUC compared to saline.
Significantly increased mechanonociceptive withdrawal latencies at 30 min and 1 h at 1 mg/kg dose.
Significantly increased mechanonociceptive withdrawal latencies at 30 min and 1 h at 3 mg/kg dose.
Produced significant AUC increases in mechanonociceptive tests at 1 mg/kg and 3 mg/kg doses.
Had its antinociceptive effect at 1 mg/kg completely prevented by co-administration with 0.3 mg/kg raclopride.

Animal Model:

Wistar (Hsd: [WI]BR) (male, 150-200 g)^[4]
Dosage:

0.01 mg/kg; 0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 2 mg/kg; 3 mg/kg
Administration:

i.p.; 1 hour prior to sacrifice (1 mg/kg); 2 hours prior to sacrifice (2, 3 mg/kg); 4 hours prior to sacrifice (0.01, 0.03, 0.1, 0.3, 1, 3 mg/kg)
Result:

Reduced cerebral hemisphere homovanillic acid (HVA) concentration by 13% at 0.03 mg/kg.
Reduced cerebral hemisphere 3,4-dihydroxyphenylacetic acid (DOPAC) concentration by 22% and HVA by 29% at 0.1 mg/kg.
Reduced hypothalamic epinephrine concentration by 41%, cerebral hemisphere DOPAC by 32%, and HVA by 43% at 0.3 mg/kg; left hypothalamic dopamine and norepinephrine concentrations unchanged.
Reduced hypothalamic epinephrine concentration by 53%, cerebral hemisphere DOPAC by 41%, and HVA by 52% at 1 mg/kg; left hypothalamic dopamine and norepinephrine concentrations unchanged.
In a separate experiment, reduced hypothalamic epinephrine by 23%, cerebral hemisphere DOPAC by 36%, and HVA by 48% at 1 mg/kg; these effects were blocked by spiperone pretreatment.
Reduced hypothalamic epinephrine concentration by 35%, hypothalamic norepinephrine by 12%, and increased hypothalamic MHPG sulfate by 85% at 2 mg/kg.
Reduced hypothalamic epinephrine concentration by 41%, cerebral hemisphere DOPAC by 26%, and HVA by 45% at 3 mg/kg; these effects were blocked by spiperone pretreatment.
In another experiment, increased hypothalamic dopamine concentration by 21%, reduced hypothalamic norepinephrine by 16%, and increased brain stem MHPG sulfate by 26% at 3 mg/kg; all these effects were blocked by spiperone pretreatment.
In a third experiment, reduced hypothalamic epinephrine by 40%, increased hypothalamic dopamine by 17%, reduced hypothalamic norepinephrine by 8%, and increased brain stem MHPG sulfate by 65% at 3 mg/kg.

Animal Model:

wild-type AB strain (both genders)^[5]
Dosage:

5.5 μM; 16.7 μM; 50 μM
Administration:

immersion; single 24-hour exposure; at 5 dpf
Result:

Increased time spent at the tank bottom in open tank test for 50 μM dose, indicating anxiety-like behavior.
Increased absolute turn angle in open tank test for 16.7 μM dose, indicating elevated erratic movements.
Increased duration and frequency of stereotypic swimming in open tank test across all doses.
Decreased test session latency compared to controls in inhibitory avoidance task.
Caused no significant changes in distance traveled, time mobile, or acceleration across all doses.
Caused no significant differences in social interaction task metrics compared to controls.
Caused no significant differences in aggression test metrics compared to controls.

Animal Model:

Macaca mulatta (male, 4-7 years old, 6-12 kg)^[6]
Dosage:

7 nmol; 35 nmol; 70 nmol
Administration:

bilateral intracerebral infusion into nucleus accumbens core; 0.2 μl/min
Result:

Reduced baseline startle amplitude on pulse-alone trial.
Disrupted PPI significantly when collapsed across all doses compared to vehicle/sham.
Disrupted PPI significantly when collapsed across 35 nM and 70 nM doses compared to vehicle/sham, with significant deficits at 8 dB and 12 dB prepulse intensities.
Reduced PPI significantly at 12 dB prepulse intensity alone at 70 nM dose compared to vehicle/sham.

Animal Model:

Wistar rats (adult male, 240 g; obsessive-compulsive disorder model via subcutaneous quinpirole injections twice weekly for 5 weeks)^[7]
Dosage:

0.5 mg/kg
Administration:

s.c.; twice weekly; 5 weeks
Result:

Increased marble burying.
Increased self-grooming activity.
Decreased time spent in open arms and decreased open arm entries in the elevated plus maze.
Showed non-significant decrease in head dipping activity in the hole board test.
Increased mRNA expression of interleukin-6 and C-reactive protein in the amygdala, with statistically insignificant increase in tumor-necrosis factor-α.
Increased neuronal nitric oxide synthase levels in the frontal cortex.
Showed non-significant changes in frontal cortex dopamine, noradrenaline, and 5-hydroxytryptamine levels.
Reduced goblet cell count and villus height/crypt depth ratio in the colon.
Decreased fecal levels of acetate, propionate, and butyrate.
Altered gut microbiota composition including increased relative abundance of Allobaculum, Bifidobacterium (specifically Bifidobacterium animalis), and decreased relative abundance of Lactobacillus (including Lactobacillus reuteri and Lactobacillus vaginalis) at the genus and species levels.

Animal Model:

C57BL/6J (male, 25-30 g)^[8]
Dosage:

2 mM; 4 mM
Administration:

intra-PVT microinjection; 0.5 μl total volume over 2 minutes
Result:

Shortened emergence time to 182.1 s (4 mM dose) compared to saline control.
Showed no significant effect on emergence time at 2 mM dose (261.3 s) relative to saline.
Did not alter isoflurane induction time at either 2 mM or 4 mM dose relative to saline.
Decreased burst suppression ratio from 42.78% pre-injection to 35.15% post-injection.
Increased mean number of c-Fos-positive nuclei in the PVT to 371.2 per mm² (4 mM dose) compared to saline control.

化学情報

CAS 番号 80373-22-4
性状 Solid
分子量 219.33
分子式 C₁₃H₂₁N₃
Color White to off-white
SMILES

CCCN1[C@@]2([H])[C@@](CCC1)([H])CC3=C(C=NN3)C2
別名

LY 171555; (-)-LY 141865
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All RT-PCRELISACell Proliferation/Viability AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Environ Sci Technol

2-Ethylhexyl Diphenyl Phosphate Causes Obesity in Zebrafish by Stimulating Overeating via Inhibition of Dopamine Receptor D2. [Abstract]

2023 Sep 26;57(38):14162-14172. PMID: 37704188

Quinpirole purchased from MedChemExpress. Usage Cited in: Environ Sci Technol. 2023 Sep 26;57(38):14162-14172. [Abstract]

DRD2 agonist Quinpirole hydrochloride (Quin) (4 μM; 7 d) significantly relieved the downregulation of drd2b in zebrafish caused by EHDPHP exposure.

Quinpirole purchased from MedChemExpress. Usage Cited in: Environ Sci Technol. 2023 Sep 26;57(38):14162-14172. [Abstract]

DRD2 agonist Quinpirole hydrochloride (Quin) (4 μM; 7 d) recovered the brain DA content of zibrafish in the 35 and 245 μg/L groups to normal levels.

Quinpirole purchased from MedChemExpress. Usage Cited in: Environ Sci Technol. 2023 Sep 26;57(38):14162-14172. [Abstract]

Quinpirole hydrochloride (Quin) (4 μM; 7 d) significantly downregulated the DA synthesis-related genes (th1 and oprd1b) and proinflammatory cytokines in zebrafish.
Br J Pharmacol

Exploiting D2 receptor β-arrestin2-biased signalling to suppress tumour growth of pituitary adenomas. [Abstract]

2021 Sep;178(17):3570-3586. PMID: 33904172

Quinpirole purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2021 Sep;178(17):3570-3586. [Abstract]

Cell viability of MMQ and GH3 cells treated with Quinpirole hydrochloride (1 nM-10 μM; 48 h) at different concentrations was assessed and normalized to DMSO (0.1%) controls.

Quinpirole purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2021 Sep;178(17):3570-3586. [Abstract]

Quinpirole hydrochloride (0.01 nM-100 μM), a selective D2 agonist, stimulated recruitment of β-arrestin2 to the D2 receptor.
Cell Rep

Dorsal BNST DRD2+ neurons mediate sex-specific anxiety-like behavior induced by chronic social isolation. [Abstract]

2023 Jul 14;42(7):112799. PMID: 37453056
J Affect Disord

Uncoupling serotonin (2C) and dopamine (D2) receptor heterodimers ameliorate PTSD-like behaviors. [Abstract]

2025 Mar 21:S0165-0327(25)00475-6. PMID: 40122260

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (455.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.5593 mL

22.7967 mL

45.5934 mL

5 mM

0.9119 mL

4.5593 mL

9.1187 mL

10 mM

0.4559 mL

2.2797 mL

4.5593 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (11.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (293 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Collier TJ, et al. Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine. Exp Neurol. 2023;369:114522. [Content Brief]

[2]. Mercado F, et al. Systemic quinpirole enhances tramadol analgesia in inflammatory pain, but not in neuropathic pain in male rats. Eur J Neurosci. 2024;60(12):7195-7210. [Content Brief]

[3]. Wang H, et al. Neuroprotective effects of quinpirole on lithium chloride pilocarpine-induced epilepsy in rats and its underlying mechanisms. Eur J Med Res. 2024;29(1):121. Published 2024 Feb 14. [Content Brief]

[4]. Fuller RW, et al. Decrease in hypothalamic epinephrine concentration and other neurochemical changes produced by quinpirole, a dopamine agonist, in rats. J Neural Transm. 1985;61(3-4):161-173. [Content Brief]

[5]. Nabinger DD, et al. Long-lasting behavioral effects of quinpirole exposure on zebrafish. Neurotoxicol Teratol. 2021;88:107034. [Content Brief]

[6]. Waguespack HF, et al. Quinpirole, but not muscimol, infused into the nucleus accumbens disrupts prepulse inhibition of the acoustic startle in rhesus macaques. Neuropharmacology. 2023;235:109563. [Content Brief]

[7]. Ghuge S, et al. Multistrain probiotic rescinds quinpirole-induced obsessive-compulsive disorder phenotypes by reshaping of microbiota gut-brain axis in rats. Pharmacol Biochem Behav. 2023;232:173652. [Content Brief]

[8]. Ao Y, et al. Application of quinpirole in the paraventricular thalamus facilitates emergence from isoflurane anesthesia in mice. Brain Behav. 2021;11(1):e01903. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.5593 mL	22.7967 mL	45.5934 mL	113.9835 mL
	5 mM	0.9119 mL	4.5593 mL	9.1187 mL	22.7967 mL
	10 mM	0.4559 mL	2.2797 mL	4.5593 mL	11.3983 mL
	15 mM	0.3040 mL	1.5198 mL	3.0396 mL	7.5989 mL
	20 mM	0.2280 mL	1.1398 mL	2.2797 mL	5.6992 mL
	25 mM	0.1824 mL	0.9119 mL	1.8237 mL	4.5593 mL
	30 mM	0.1520 mL	0.7599 mL	1.5198 mL	3.7994 mL
	40 mM	0.1140 mL	0.5699 mL	1.1398 mL	2.8496 mL
	50 mM	0.0912 mL	0.4559 mL	0.9119 mL	2.2797 mL
	60 mM	0.0760 mL	0.3799 mL	0.7599 mL	1.8997 mL
	80 mM	0.0570 mL	0.2850 mL	0.5699 mL	1.4248 mL
	100 mM	0.0456 mL	0.2280 mL	0.4559 mL	1.1398 mL

Quinpirole

4 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Quinpirole

Apoptosis Compound Library

GPCR/G Protein Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

Neurotransmitter Receptor Compound Library

Neuroprotective Compound Library

Anti-Parkinson's Disease Compound Library

Mitochondria-Targeted Compound Library

Antidepressant Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Dopamine Receptor Compound Library

Ion Channel Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 Quinpirole

Dopamine Receptor アイソフォーム固有の製品をすべて表示

Calcium Channel アイソフォーム固有の製品をすべて表示

Bcl-2 Family アイソフォーム固有の製品をすべて表示

iGluR アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (4)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Quinpirole

Apoptosis Compound Library

GPCR/G Protein Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

Neurotransmitter Receptor Compound Library

Neuroprotective Compound Library

Anti-Parkinson's Disease Compound Library

Mitochondria-Targeted Compound Library

Antidepressant Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Dopamine Receptor Compound Library

Ion Channel Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 Quinpirole

Dopamine Receptor アイソフォーム固有の製品をすべて表示

Calcium Channel アイソフォーム固有の製品をすべて表示

Bcl-2 Family アイソフォーム固有の製品をすべて表示

iGluR アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (4)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Quinpirole 関連分類

製品番号: HY-B1752